Clinical Trials Logo

Filter by:
NCT ID: NCT02475798 No longer available - Iliac Aneurysms Clinical Trials

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this extended study is to collect confirmatory safety and effectiveness data on the Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the commercially available Atrium iCAST™ covered stent in the treatment of aortoiliac and iliac aneurysms.

NCT ID: NCT02474121 No longer available - Clinical trials for Peripheral Arterial Disease

Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access

MOBILE-CA
Start date: n/a
Phase:
Study type: Expanded Access

This study will continue to evaluate the performance of the MarrowStim™ PAD Kit to treat subjects with critical limb ischemia (CLI) caused by severe PAD.

NCT ID: NCT02473653 No longer available - Metastatic Cancer Clinical Trials

Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

Immune-based therapies (vaccines) are a new focus of clinical investigation. These therapies try to assist a patient's immune system (a system in our bodies that protects us against infection) in killing tumors. One form of such therapy is the dendritic cell combined with HER-2/neu (a type of protein over-expressed in some cancers) vaccine. Dendritic cells are immune cells that can tell your immune system to fight infection. In laboratory testing, these cells may also help the immune system attack tumors such as breast, kidney cancer or skin cancer. The purpose of this research study is to determine if it is both possible and safe to administer" this vaccine to patients with any HER2+ cancer.

NCT ID: NCT02473497 No longer available - Neoplasm Clinical Trials

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Start date: n/a
Phase:
Study type: Expanded Access

This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal translocation or activating mutation involving the ALK or ROS1 gene or an activating genetic alteration involving the cMET gene who cannot swallow the crizotinib capsule but may be able to derive benefit from treatment with an alternative oral formulation of crizotinib.

NCT ID: NCT02461706 No longer available - Epilepsy Clinical Trials

Treatment of Drug Resistant Epilepsy

Cannabidiol
Start date: n/a
Phase:
Study type: Expanded Access

The main goal of this study is to provide treatment with cannabidiol (CBD) to children with drug resistant epilepsy through a Physician Expanded Access Investigation New Drug protocol. As the controlled therapeutic use of CBD in children is novel, the primary objective of this study is to evaluate the safety and efficacy of CBD when administered as adjunctive therapy in children that have exhausted the majority of FDA approved antiepileptic drug treatment options.

NCT ID: NCT02451852 No longer available - Clinical trials for EGFR T790M Mutation Positive NSCLC

AZD9291 US Expanded Access Program

Start date: n/a
Phase: N/A
Study type: Expanded Access

To provide access to AZD9291 for adult patients with advanced/metastatic, epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

NCT ID: NCT02389933 No longer available - Clinical trials for Heart Failure With Reduced Ejection Fraction (HF-rEF)

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Start date: n/a
Phase:
Study type: Expanded Access

Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.

NCT ID: NCT02358018 No longer available - Clinical trials for Neuroendocrine Tumors

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor. 68Ga-DOTATOC is an improved imaging agent being routinely used in many centers outside the USA, with better tumor detection than with OctreoScan.

NCT ID: NCT02354612 No longer available - Solid Tumors Clinical Trials

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Start date: n/a
Phase:
Study type: Expanded Access

Open-label, continuation study

NCT ID: NCT02312037 No longer available - Clinical trials for CD33 Positive Acute Myelogenous Leukemia

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

AML
Start date: n/a
Phase:
Study type: Expanded Access

An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com